No significant association between the promoter region polymorphisms of factor VII gene and risk of venous thrombosis in cancer patients.
Factor VII (FVII) plays an important role in blood coagulation. The role of common polymorphisms influencing the FVII plasma levels in thromboembolic disorders has been evaluated but there is no published data related to the effect of FVII gene polymorphisms on the venous thrombosis risk in cancer. To investigate the association of three common functional polymorphisms in the promoter region of FVII gene: a decanucleotide insertion at position-323 (-323ins10-bp), a G to T substitution at position-401 (-401GT), and a G to A substitution at position-402 (-401GT) with venous thrombosis in cancer patients. The study included 60 cancer patients with venous thromboembolism (VTE) (group 1) and 130 cancer patients without VTE (group 2). Genotyping of -323ins10-bp, -401GT, and -402GA polymorphisms in the promoter region of FVII gene was performed by the method of single-strand conformation polymorphism analysis and sequencing. Factor V Leiden (FVL) was also determined in all cases. The frequency of FVL was significantly greater in cancer patients with VTE compared with group 2 patients (p FVII gene, the distributions of genotypes and allele frequencies were not significantly different between two groups of patients ( p > 0.05). The results did not change significantly after the exclusion of patients carrying the FVL (p > 0.05). The screening for the -323ins10-bp, -401GT, and -402GA olymorphisms of FVII gene did not contribute to a meaningful diagnostic nvestigation in cancer patients with venous thrombosis.